NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free ENLV Stock Alerts $3.76 -0.10 (-2.59%) (As of 10:48 AM ET) Add Compare Share Share Today's Range$3.70▼$3.8250-Day Range$2.54▼$4.3052-Week Range$1.20▼$4.37Volume64,721 shsAverage Volume93,262 shsMarket Capitalization$69.82 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enlivex Therapeutics alerts: Email Address Enlivex Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside219.1% Upside$12.00 Price TargetShort InterestHealthy1.41% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.36) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.00 out of 5 starsMedical Sector749th out of 939 stocksPharmaceutical Preparations Industry344th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingEnlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Enlivex Therapeutics has a forecasted upside of 219.1% from its current price of $3.76.Amount of Analyst CoverageEnlivex Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.41% of the outstanding shares of Enlivex Therapeutics have been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently increased by 15.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENLV. Previous Next 2.3 News and Social Media Coverage News SentimentEnlivex Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enlivex Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for ENLV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.02% of the stock of Enlivex Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($1.36) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Enlivex Therapeutics Stock (NASDAQ:ENLV)Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Read More ENLV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENLV Stock News HeadlinesMarch 22, 2024 | finanznachrichten.deEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 16, 2024 | finance.yahoo.comENLV Apr 2024 7.500 callMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 9, 2024 | edition.cnn.comEnlivex Therapeutics Ltd.February 26, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee OsteoarthritisFebruary 22, 2024 | benzinga.comEnlivex Therapeutics Stock (NASDAQ:ENLV), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comENLV May 2024 5.000 putFebruary 7, 2024 | finance.yahoo.comEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.January 17, 2024 | finance.yahoo.comEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisDecember 20, 2023 | finance.yahoo.comEnlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With SepsisDecember 16, 2023 | morningstar.comEnlivex Therapeutics Ltd ENLVDecember 12, 2023 | finance.yahoo.comIs Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?November 21, 2023 | finance.yahoo.comMediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial OfficerSeptember 11, 2023 | finance.yahoo.comEnlivex Announces Reprioritization Plan and Second Quarter 2023 Financial ResultsSeptember 7, 2023 | finance.yahoo.comEnlivex to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 2, 2023 | finance.yahoo.comEnlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19July 31, 2023 | finance.yahoo.comEnlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With SepsisJune 26, 2023 | finance.yahoo.comEnlivex Announces First Quarter 2023 Financial Results and Provides a Business UpdateJune 16, 2023 | benzinga.comThis Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To CancerJune 6, 2023 | finance.yahoo.comEnlivex to Present at the 2023 Jefferies Healthcare ConferenceMay 31, 2023 | finance.yahoo.comEnlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene TherapyMay 8, 2023 | finance.yahoo.comEnlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell TherapyApril 20, 2023 | marketwatch.comEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra(TM) in Patients Receiving CAR T-Cell TherapyApril 19, 2023 | finance.yahoo.comEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell TherapyApril 17, 2023 | finance.yahoo.comEnlivex Appoints Andrew Singer to its Board of DirectorsApril 14, 2023 | finance.yahoo.comAnalysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical TrialsSee More Headlines Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/26/2023Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENLV CUSIPN/A CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+214.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.02% Return on Assets-47.73% Debt Debt-to-Equity RatioN/A Current Ratio7.34 Quick Ratio7.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book1.24Miscellaneous Outstanding Shares18,570,000Free Float16,286,000Market Cap$70.94 million OptionableOptionable Beta1.01 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Shai Novik M.B.A. (Age 58)Executive Chairman Comp: $528kDr. Oren Hershkovitz Ph.D. (Age 47)Chief Executive Officer Comp: $273.6kProf. Dror Mevorach M.D. (Age 68)Founder and Chief Scientific & Medical Officer Comp: $180kMs. Shachar Shlosberger CPA (Age 47)Chief Financial Officer Comp: $126kMr. Veronique Amor-BaroukhSenior Director of OperationsMs. Sigal AradDirector of HRMore ExecutivesKey CompetitorsOncolytics BiotechNASDAQ:ONCYEliem TherapeuticsNASDAQ:ELYMBioLineRxNASDAQ:BLRXAffimedNASDAQ:AFMDLifeVantageNASDAQ:LFVNView All Competitors ENLV Stock Analysis - Frequently Asked Questions Should I buy or sell Enlivex Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENLV shares. View ENLV analyst ratings or view top-rated stocks. What is Enlivex Therapeutics' stock price target for 2024? 1 analysts have issued 12-month price targets for Enlivex Therapeutics' shares. Their ENLV share price targets range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 219.1% from the stock's current price. View analysts price targets for ENLV or view top-rated stocks among Wall Street analysts. How have ENLV shares performed in 2024? Enlivex Therapeutics' stock was trading at $2.70 at the beginning of the year. Since then, ENLV shares have increased by 39.3% and is now trading at $3.76. View the best growth stocks for 2024 here. Are investors shorting Enlivex Therapeutics? Enlivex Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 261,500 shares, an increase of 15.4% from the February 29th total of 226,600 shares. Based on an average trading volume of 108,300 shares, the days-to-cover ratio is presently 2.4 days. View Enlivex Therapeutics' Short Interest. When is Enlivex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our ENLV earnings forecast. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its quarterly earnings results on Monday, June, 26th. The company reported ($0.40) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.40). What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). Who are Enlivex Therapeutics' major shareholders? Enlivex Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENLV) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.